8-K: Lifecore Biomedical Faces Potential Nasdaq Delisting Due to Late Financial Filings

Lifecore Biomedical has received a delisting notice from Nasdaq due to the late filing of its annual and quarterly financial reports, and intends to appeal the decision.

Summary

• Lifecore Biomedical received a Staff Delisting Determination from Nasdaq because it failed to file its annual report for the fiscal year ended May 28, 2023, and quarterly reports for the periods ended August 27, 2023, and November 29, 2023.
• The company was granted an extension until February 12, 2024, to file these reports, but missed the deadline.
• Lifecore intends to appeal the delisting decision and request a stay of any suspension or delisting action pending the hearing process.
• The company is working with its auditors to complete a restatement of previously issued financial statements and file the overdue reports.
• A hearing request must be made by February 20, 2024, which will automatically stay the suspension for 15 days.
• Hearings are typically scheduled 30-45 days after the hearing request, and the company may further appeal to the Nasdaq Listing Council.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the company's failure to meet reporting deadlines. While the company is taking steps to appeal, the situation creates uncertainty and risk for investors.

Positives

• The delisting notice does not immediately suspend trading of Lifecore's securities.
• Lifecore is actively working with auditors to complete the restatement and file the overdue reports.
• The company intends to appeal the delisting decision and request a stay, which could allow them more time to regain compliance.
• The company has a process to appeal the decision to the Nasdaq Listing Council if required.

Negatives

• Lifecore has failed to meet the deadline for filing its annual and quarterly financial reports.
• The company is facing potential delisting from Nasdaq due to non-compliance with listing rules.
• There is no guarantee that the company will be able to file the reports before a hearing or that the hearing panel will grant a stay.
• The company has previously disclosed delays in filing these reports.

Risks

• There is a risk that Lifecore may not be able to file the required financial reports in time to avoid delisting.
• The Nasdaq Hearing Panel may not grant the company's request for a stay pending the hearing process.
• The company's securities could be suspended or delisted from Nasdaq if they fail to regain compliance.
• The restatement of financial statements could take longer than expected, further delaying the filing of reports.

Future Outlook

The company is focused on completing the restatement of its financial statements and filing the overdue reports to regain compliance with Nasdaq listing rules, but there is no guarantee of success.

Management Comments

• The Company intends to appeal the Staff Determination before a Nasdaq Hearing Panel and seek a further stay of any suspension or delisting action pending the hearing process.
• The Company is working diligently with its auditors to complete the previously disclosed restatement and to file the Form 10-K, First Quarter 10-Q and Second Quarter 10-Q.

Industry Context

This situation highlights the importance of timely financial reporting for publicly listed companies and the consequences of non-compliance with exchange listing rules. It is not uncommon for companies to face delisting threats due to late filings, especially when restatements are involved.

Comparison to Industry Standards

• Many companies in the pharmaceutical and biotech industry, such as Catalent and Lonza, are expected to file their financial reports on time.
• Delays in financial reporting are often viewed negatively by investors and can lead to a loss of confidence in the company's management and financial controls.
• Companies that fail to meet Nasdaq's listing requirements risk being delisted, which can significantly impact their ability to raise capital and maintain investor confidence.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty about the company's future.
• Customers and suppliers may be concerned about the company's stability.

Next Steps

• Lifecore must submit a hearing request to Nasdaq by February 20, 2024.
• The company will work to complete the restatement of its financial statements.
• Lifecore will file the overdue annual and quarterly reports.
• The company will attend a hearing before the Nasdaq Hearing Panel.
• Lifecore may appeal the Hearing Panel's decision to the Nasdaq Listing Council.

Key Dates

Keywords

delisting, Nasdaq, financial reporting, late filing, appeal, restatement, compliance, hearing, Form 10-K, Form 10-Q